Corporate governance

According to the Articles of Association, the Board of Directors of the Company shall have three (3) to eight (8) members with a maximum of two (2) deputies. Board members and deputies are elected by the Annual General Meeting. The Board’s assignment is valid until the next Annual General Meeting. The management and all board members can be reached via the Company’s head office at Gasverksgatan 1, 222 29, Lund. The Board’s work is governed by the Swedish Companies Act, the Articles of Association and the rules of procedure produced by the Board.


Articles of  association

The articles of association are a set of regulations, which together with legislation, specify the framework for the business. The articles of association for NanoEcho AB (publ), (556951–9845), were approved at an extraordinary general meeting on 18 November 2021.


Management and board

The management consists of people with solid experience and knowledge in medical technology and commercialization. There is also a background of successfully driving products from idea stage to successful launches

Board of directors

Dr. Linda Persson

Number of shares in NanoEcho:  50,000

Linda Persson has a PhD in medical technology and has extensive experience from several leading positions with focus on product development. She comes most recently from a senior role in the strategy and business development department at E.ON. Before that, Linda also held influential positions at other companies, such as Baxter and Sony

Magnus Santesson

Number of shares in NanoEcho 66,000

Magnus Santesson is educated at Lund University in computer science. Magnus has solid experience as a program and project manager for technical global development projects in fast-moving consumer goods and medical technology. He co-founded and developed Mobytech Consulting, which had 28 employees before it was sold to a French consulting company.

Henrik Ljung

Number of shares in NanoEcho:
21,953 (via Ljung & Winbladh AB)

Henrik Ljung has an MBA and has several years of experience as the CFO of Cerdo Bankpartner AB, Acconeer AB, Ballingslöv AB, Sardus AB, and Malmöhus Invest AB, among others.

Kristina Hallström

Number of shares in NanoEcho: 40,000

Kristina Hallström holds a Master of Business Administration from Lund University as well as an exam in physiotherapy. She has extensive experience from marketing strategy, marketing communication, PR, regulatory and clinical affairs from the international MedTech industry in companies such as Arjo, Getinge, ProstaLund and Care of Sweden. Kristina is responsible for marketing & communications and quality & regulatory affairs.

Dr. Ulrika Axelsson
Clinical Director

Number of shares in NanoEcho:

Ulrika Axelsson has a Ph.D. in Immunotechnology and has experience in running clinical trials. Most recently she had a position as business coach at SmiLe Life Science Incubator. Before that, Ulrika worked at PainDrainer AB and in leading positions at CREATE Health Translational Cancer Center, with the aim of commercializing research in oncology.


Daniel Johnsson
Chariman of the board

Number of shares in NanoEcho: 5,933,355 via Quiq Holding AB

University studies at Chalmers University of Technology and the Gothenburg School of Business. 25 years of experience as CEO of Exertis Nordics AB, of which the last 7 years in a listed group. He has a history of being a serial entrepreneur with several successful exits. Today active as investor and adviser.

Chairman of the Board in: Oblique Therapeutics AB (publ), Postery AB, Renable AB, Admazing AB. Board member in: Quiq Holding AB, Flower Infrastructure Technologies AB, Playground TV AB, Chillimobil AB, Workpilots Oy.

Dr. Ann-Christin Malmborg Hager
Member of the board

Number of  shares in NanoEcho: 0

Has long experience in starting companies in life science. Previous experience includes CEO of PainDrainer AB, SenzaGen AB, DiaProst AB, Cantargia AB and XImmune AB. She has worked as Investment Director at LU Bioscience and VP Business Development at Alligator Bioscience AB. Today she works as CEO at Uptake Bio AB, advisory to start-up companies, and Board Member of SenzaGen AB, Avena Partners AB, Colzyx AB, and Hager Consulting AB.

Dependent in relation to the Company and to major shareholders.

Independent in relation to the Company and to major shareholders.

Dr. Masoud Khayyami
Member of the board

Number of shares in NanoEcho:  2,754,696
private, via related and via MTT Capital AB

Masoud has a PhD in technical chemistry and has solid experience from research in medical technology and biotechnology. Masoud has entrepreneurial experience in companies such as Lumito AB, Gasporox AB and Prolight Diagnostics AB. Today, Masoud works as CEO of Cardeon AB (publ), SpectraCure AB (publ), and MK Capital Invest AB. 

Chairman of the board in Prolight Diagnostics AB (publ), and member of the board in SpectraCure AB (publ), TEQCool AB (publ) and MTT Capital AB.


Sebastian Clausin
Member of the board

Number of shares in NanoEcho590,000
via  Kogai Invest AB

Sebastian has extensive experience from the IT industry and has worked in roles such as Senior Technical Account Manager and Solution Architect for large organizations. Since 2015, Sebastian has devoted himself to his own investments, with a focus on small- and mid-cap companies. 

Sebastian is a board member and CEO of Kogai Invest AB.

The election committee’s proposal for new elections

Åke Bengtsson

Number of shares in NanoEcho: 0

Åke has a long experience in executive roles as CFO and CEO at various manufacturing industries with an international footprint. Åke holds an Executive MBA from SIMI Copenhagen. He currently run his own business offering interim services in business advisory and management. Åke is a Business Coach at Produktionsänglar, Södertälje Science Park, and Senior Business Advisor at SMILE Incubator. Åke is a board member of Nosterix AB.


Tord Labuda

Number of shares in NanoEcho: 0

Tord has a Ph.D. in Tumor Immunology from Lund University and has more than 15 years of international experience from leading positions in the pharmaceutical industry, primarily in R&D but also in commercial roles. Today, Tord is operational as Vice President and Global Head of Clinical Development at LEO Pharma in Denmark. Tord’s passion lies in leadership, strategic guidance to new patient solutions, and creating commercial value.

Independent in relation to the Company and to major shareholders.

Independent in relation to the Company and to major shareholders. använder cookies för att förbättra hemsidans funktionalitet för dig som användare. Är det okej?